Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07JAN
|
|||
Former ID |
DIB020928
|
|||
Drug Name |
SCH 206272
|
|||
Synonyms |
SCH-206272
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C33H41Cl4N5O4
|
|||
Canonical SMILES |
CNC(=O)CC1CCCN(C1=O)C2CCN(CC2)CCC(C3=CC(=C(C=C3)Cl)Cl)C(=NOC)CN(C)C(=O)C4=CC(=CC(=C4)Cl)Cl
|
|||
InChI |
1S/C33H41Cl4N5O4/c1-38-31(43)18-22-5-4-11-42(33(22)45)26-8-12-41(13-9-26)14-10-27(21-6-7-28(36)29(37)17-21)30(39-46-3)20-40(2)32(44)23-15-24(34)19-25(35)16-23/h6-7,15-17,19,22,26-27H,4-5,8-14,18,20H2,1-3H3,(H,38,43)/b39-30-/t22-,27-/m1/s1
|
|||
InChIKey |
UITMLIVWRRGLLR-MSBPVHBISA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neuromedin-K receptor (TACR3) | Target Info | Antagonist | [2] |
Substance-K receptor (TACR2) | Target Info | Antagonist | [2] | |
Substance-P receptor (TACR1) | Target Info | Antagonist | [2] | |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Measles | ||||
Panther Pathway | CCKR signaling map ST | |||
Reactome | G alpha (q) signalling events | |||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
SIDS Susceptibility Pathways | ||||
Spinal Cord Injury |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2106). | |||
REF 2 | SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.